Get started
Author

Mari Pesonen

Observed names: PESONEN, MARI, Pesonen, Mari
ORCID: 0000-0003-4299-3488
Observed ORCID: 0000-0003-4299-3488
OpenAlex ID: A5068523362
Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
2023 · Taru Hallinen, Santtu Kivelä, et al. · ClinicoEconomics and Outcomes Research · 14
PDF
Cost‐effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov‐model
2021 · Mari Pesonen, Eila Kankaanpää, et al. · Acta Ophthalmologica · 8
PDF
Adverse drug events in cost-effectiveness analyses of interventions for diabetic conditions: a scoping review protocol
2022 · Mari Pesonen, Eila Kankaanpää, et al. · JBI Evidence Synthesis · 5
Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review
2024 · Mari Pesonen, Virpi Jylhä, et al. · JBI Evidence Synthesis · 2
Sensitivity of Cost-Effectiveness to Inclusion of Adverse Drug Events: A Scoping Review of Economic Models of Pharmacological Interventions for Diabetes, Diabetic Retinopathy, and Diabetic Macular Edema
2025 · Mari Pesonen, Eila Kankaanpää · ClinicoEconomics and Outcomes Research · 1
PDF
Wealth of information and poverty of attention? Managing the inherent challenges of large scoping reviews
2024 · Mari Pesonen · JBI Evidence Synthesis
Patients with Chronic Kidney Disease: Background Factors Associated with Experienced Health Status and Life Satisfaction
2024 · Mari Pesonen, Aino Vesikansa, et al. · Patient Related Outcome Measures
PDF
Europeanisation of Regional Policy and Governance in Finland - The Case of Saarijärvi-Viitasaari Sub-Region
2010 · PESONEN, MARI · Tampere University Institutional Repository (Tampere University)
Works count: 10
Citation count: 30
H-index: 3
I10-index: 1
Year
Topic
Type